Mo Eun Yeong, Lee Ji Young, Kim Su Yeon, Kim Min Ji, Kim Eun Sook, Lee Seungok, Han Je Ho, Moon Sung Dae
Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Department of Laboratory Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Endocrinol Metab (Seoul). 2018 Sep;33(3):413-422. doi: 10.3803/EnM.2018.33.3.413.
We previously reported a patient with congenital adrenal hyperplasia (CAH) with compound heterozygous mutations in the cytochrome P450 17A1 () gene. One allele had a p.His373Leu and the other a new p.Glu383fsX36 mutation. The aim of this study was to investigate the functional properties of a new allele present in a compound heterozygote of .
To understand how p.His373Leu and p.Glu383fsX36 affect P450c17 enzymatic activity, wild type and mutant cDNAs were cloned into flag-tagged pcDNA3 vector and introduced into human embryonic kidney cells 293T (HEK293T) cells. Protein expression levels of CYP17A1 were then analyzed. And the activities of 17α-hydroxylase and 17,20-lyase of CYP17A1 were evaluated by measuring the conversion of progesterone to 17α-hydroxyprogesterone and of 17α-hydroxypregnenolone to dehydroepiandrosterone, respectively. In addition a computer model was used to create the three-dimensional structure of the mutant CYP17A1 enzymes.
Production of the p.His373Leu mutant protein was significantly lower than that of the wild type protein, and the p.Glu383fsX36 protein was hardly produced. Similarly the enzymatic activity derived from the p.His373Leu mutant vector was significantly lower than that obtained from the wild type vector, and little activity was obtained from the p.Glu383fsX36 vector. Three-dimensional modeling of the enzyme showed that p.His373 was located in region important for heme-binding and proper folding. Neither the p.His373Leu nor the p.Glu383fsX36 mutant protein formed a heme-binding structure.
Enzyme activity measured in both mutants disappeared completely in both 17α-hydroxylase and 17,20-lyase. This result accounts for the clinical manifestations of the patient with the compound heterozygous mutations.
我们之前报道过一名先天性肾上腺皮质增生症(CAH)患者,其细胞色素P450 17A1()基因存在复合杂合突变。一个等位基因发生了p.His373Leu突变,另一个发生了新的p.Glu383fsX36突变。本研究的目的是探究存在于复合杂合子中的新等位基因的功能特性。
为了解p.His373Leu和p.Glu383fsX36如何影响P450c17酶活性,将野生型和突变型cDNA克隆到带有标签的pcDNA3载体中,并导入人胚肾细胞293T(HEK293T)。然后分析CYP17A1的蛋白表达水平。通过分别测量孕酮向17α-羟孕酮的转化以及17α-羟孕烯醇酮向脱氢表雄酮的转化,评估CYP17A1的17α-羟化酶和17,20-裂解酶活性。此外,使用计算机模型构建突变型CYP17A1酶的三维结构。
p.His373Leu突变蛋白的产生显著低于野生型蛋白,而p.Glu383fsX36蛋白几乎不产生。同样,来自p.His373Leu突变载体的酶活性显著低于野生型载体,且p.Glu383fsX36载体几乎没有活性。酶的三维建模显示,p.His373位于对血红素结合和正确折叠重要的区域。p.His373Leu和p.Glu383fsX36突变蛋白均未形成血红素结合结构。
在两个突变体中测得的酶活性在17α-羟化酶和17,20-裂解酶中均完全消失。这一结果解释了该复合杂合突变患者的临床表现。